NASDAQ:ICUI

ICU Medical Competitors

$207.89
+1.89 (+0.92 %)
(As of 04/14/2021 12:15 PM ET)
Add
Compare
Today's Range
$205.19
Now: $207.89
$208.70
50-Day Range
$197.58
MA: $206.28
$219.54
52-Week Range
$170.57
Now: $207.89
$236.51
Volume185 shs
Average Volume122,454 shs
Market Capitalization$4.41 billion
P/E Ratio55.00
Dividend YieldN/A
Beta0.72

Competitors

ICU Medical (NASDAQ:ICUI) Vs. ALGN, WST, COO, XRAY, HAE, and QDEL

Should you be buying ICUI stock or one of its competitors? Companies in the sub-industry of "health care supplies" are considered alternatives and competitors to ICU Medical, including Align Technology (ALGN), West Pharmaceutical Services (WST), The Cooper Companies (COO), DENTSPLY SIRONA (XRAY), Haemonetics (HAE), and Quidel (QDEL).

Align Technology (NASDAQ:ALGN) and ICU Medical (NASDAQ:ICUI) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Institutional and Insider Ownership

85.8% of Align Technology shares are owned by institutional investors. Comparatively, 91.5% of ICU Medical shares are owned by institutional investors. 1.2% of Align Technology shares are owned by company insiders. Comparatively, 10.9% of ICU Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Align Technology and ICU Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Align Technology76.00%68.99%46.64%
ICU Medical6.43%9.73%7.70%

Risk & Volatility

Align Technology has a beta of 1.68, suggesting that its stock price is 68% more volatile than the S&P 500. Comparatively, ICU Medical has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500.

Earnings and Valuation

This table compares Align Technology and ICU Medical's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Align Technology$2.41 billion19.57$442.78 million$4.96120.01
ICU Medical$1.27 billion3.48$101.04 million$7.3628.25

Align Technology has higher revenue and earnings than ICU Medical. ICU Medical is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Align Technology and ICU Medical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Align Technology13902.62
ICU Medical00203.00

Align Technology currently has a consensus price target of $501.3333, suggesting a potential downside of 15.77%. ICU Medical has a consensus price target of $240.50, suggesting a potential upside of 15.69%. Given ICU Medical's stronger consensus rating and higher probable upside, analysts plainly believe ICU Medical is more favorable than Align Technology.

Summary

Align Technology beats ICU Medical on 8 of the 14 factors compared between the two stocks.

ICU Medical (NASDAQ:ICUI) and West Pharmaceutical Services (NYSE:WST) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for ICU Medical and West Pharmaceutical Services, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ICU Medical00203.00
West Pharmaceutical Services01202.67

ICU Medical currently has a consensus target price of $240.50, suggesting a potential upside of 15.69%. West Pharmaceutical Services has a consensus target price of $310.00, suggesting a potential upside of 2.35%. Given ICU Medical's stronger consensus rating and higher possible upside, equities analysts plainly believe ICU Medical is more favorable than West Pharmaceutical Services.

Earnings and Valuation

This table compares ICU Medical and West Pharmaceutical Services' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ICU Medical$1.27 billion3.48$101.04 million$7.3628.25
West Pharmaceutical Services$1.84 billion12.16$241.70 million$3.2493.48

West Pharmaceutical Services has higher revenue and earnings than ICU Medical. ICU Medical is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

91.5% of ICU Medical shares are held by institutional investors. Comparatively, 92.6% of West Pharmaceutical Services shares are held by institutional investors. 10.9% of ICU Medical shares are held by insiders. Comparatively, 1.6% of West Pharmaceutical Services shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

ICU Medical has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, West Pharmaceutical Services has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500.

Profitability

This table compares ICU Medical and West Pharmaceutical Services' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ICU Medical6.43%9.73%7.70%
West Pharmaceutical Services14.69%19.01%12.78%

Summary

West Pharmaceutical Services beats ICU Medical on 9 of the 13 factors compared between the two stocks.

The Cooper Companies (NYSE:COO) and ICU Medical (NASDAQ:ICUI) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, profitability, earnings and institutional ownership.

Risk & Volatility

The Cooper Companies has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Comparatively, ICU Medical has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.

Institutional & Insider Ownership

95.8% of The Cooper Companies shares are owned by institutional investors. Comparatively, 91.5% of ICU Medical shares are owned by institutional investors. 1.4% of The Cooper Companies shares are owned by insiders. Comparatively, 10.9% of ICU Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares The Cooper Companies and ICU Medical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The Cooper Companies$2.43 billion7.87$238.40 million$9.6440.37
ICU Medical$1.27 billion3.48$101.04 million$7.3628.25

The Cooper Companies has higher revenue and earnings than ICU Medical. ICU Medical is trading at a lower price-to-earnings ratio than The Cooper Companies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares The Cooper Companies and ICU Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
The Cooper Companies9.81%12.79%7.20%
ICU Medical6.43%9.73%7.70%

Analyst Ratings

This is a breakdown of current recommendations and price targets for The Cooper Companies and ICU Medical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
The Cooper Companies04602.60
ICU Medical00203.00

The Cooper Companies currently has a consensus target price of $384.25, indicating a potential downside of 1.26%. ICU Medical has a consensus target price of $240.50, indicating a potential upside of 15.69%. Given ICU Medical's stronger consensus rating and higher possible upside, analysts clearly believe ICU Medical is more favorable than The Cooper Companies.

Summary

The Cooper Companies beats ICU Medical on 10 of the 14 factors compared between the two stocks.

ICU Medical (NASDAQ:ICUI) and DENTSPLY SIRONA (NASDAQ:XRAY) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation and risk.

Institutional and Insider Ownership

91.5% of ICU Medical shares are held by institutional investors. Comparatively, 96.0% of DENTSPLY SIRONA shares are held by institutional investors. 10.9% of ICU Medical shares are held by insiders. Comparatively, 0.5% of DENTSPLY SIRONA shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for ICU Medical and DENTSPLY SIRONA, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ICU Medical00203.00
DENTSPLY SIRONA15702.46

ICU Medical presently has a consensus target price of $240.50, indicating a potential upside of 15.69%. DENTSPLY SIRONA has a consensus target price of $55.3333, indicating a potential downside of 14.87%. Given ICU Medical's stronger consensus rating and higher probable upside, equities analysts plainly believe ICU Medical is more favorable than DENTSPLY SIRONA.

Valuation & Earnings

This table compares ICU Medical and DENTSPLY SIRONA's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ICU Medical$1.27 billion3.48$101.04 million$7.3628.25
DENTSPLY SIRONA$4.03 billion3.53$262.90 million$2.4526.53

DENTSPLY SIRONA has higher revenue and earnings than ICU Medical. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than ICU Medical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ICU Medical and DENTSPLY SIRONA's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ICU Medical6.43%9.73%7.70%
DENTSPLY SIRONA-1.40%7.13%4.13%

Volatility & Risk

ICU Medical has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, DENTSPLY SIRONA has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500.

Summary

ICU Medical beats DENTSPLY SIRONA on 8 of the 14 factors compared between the two stocks.

Haemonetics (NYSE:HAE) and ICU Medical (NASDAQ:ICUI) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.

Earnings and Valuation

This table compares Haemonetics and ICU Medical's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Haemonetics$988.48 million6.03$76.53 million$3.3135.42
ICU Medical$1.27 billion3.48$101.04 million$7.3628.25

ICU Medical has higher revenue and earnings than Haemonetics. ICU Medical is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Haemonetics has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, ICU Medical has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Haemonetics and ICU Medical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Haemonetics00403.00
ICU Medical00203.00

Haemonetics presently has a consensus target price of $144.80, suggesting a potential upside of 23.51%. ICU Medical has a consensus target price of $240.50, suggesting a potential upside of 15.69%. Given Haemonetics' higher possible upside, research analysts plainly believe Haemonetics is more favorable than ICU Medical.

Institutional and Insider Ownership

96.2% of Haemonetics shares are owned by institutional investors. Comparatively, 91.5% of ICU Medical shares are owned by institutional investors. 1.6% of Haemonetics shares are owned by insiders. Comparatively, 10.9% of ICU Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Haemonetics and ICU Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Haemonetics11.76%22.85%10.40%
ICU Medical6.43%9.73%7.70%

Summary

Haemonetics beats ICU Medical on 8 of the 13 factors compared between the two stocks.

ICU Medical (NASDAQ:ICUI) and Quidel (NASDAQ:QDEL) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Volatility and Risk

ICU Medical has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, Quidel has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500.

Profitability

This table compares ICU Medical and Quidel's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ICU Medical6.43%9.73%7.70%
Quidel36.91%63.31%40.55%

Analyst Recommendations

This is a summary of recent ratings and target prices for ICU Medical and Quidel, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ICU Medical00203.00
Quidel10302.50

ICU Medical currently has a consensus target price of $240.50, suggesting a potential upside of 15.69%. Quidel has a consensus target price of $262.75, suggesting a potential upside of 103.60%. Given Quidel's higher possible upside, analysts clearly believe Quidel is more favorable than ICU Medical.

Insider and Institutional Ownership

91.5% of ICU Medical shares are held by institutional investors. Comparatively, 84.0% of Quidel shares are held by institutional investors. 10.9% of ICU Medical shares are held by company insiders. Comparatively, 14.1% of Quidel shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares ICU Medical and Quidel's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ICU Medical$1.27 billion3.48$101.04 million$7.3628.25
Quidel$534.89 million10.21$72.92 million$2.7347.27

ICU Medical has higher revenue and earnings than Quidel. ICU Medical is trading at a lower price-to-earnings ratio than Quidel, indicating that it is currently the more affordable of the two stocks.


ICU Medical Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Align Technology logo
ALGN
Align Technology
1.9$595.23+0.1%$47.14 billion$2.41 billion27.08
West Pharmaceutical Services logo
WST
West Pharmaceutical Services
1.9$302.87+1.2%$22.63 billion$1.84 billion79.91
The Cooper Companies logo
COO
The Cooper Companies
1.9$389.16+0.4%$19.21 billion$2.43 billion80.91
DENTSPLY SIRONA logo
XRAY
DENTSPLY SIRONA
2.0$65.00+1.8%$13.99 billion$4.03 billion-282.61Decrease in Short Interest
Haemonetics logo
HAE
Haemonetics
1.6$117.24+0.3%$5.97 billion$988.48 million56.64
Quidel logo
QDEL
Quidel
2.4$129.05+0.4%$5.48 billion$534.89 million15.15
STAAR Surgical logo
STAA
STAAR Surgical
1.4$116.97+1.1%$5.38 billion$150.18 million615.66Increase in Short Interest
Neogen logo
NEOG
Neogen
1.2$93.79+0.5%$4.99 billion$418.17 million82.27
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.5$61.74+1.3%$3.39 billion$994.85 million-116.49
Atrion logo
ATRI
Atrion
1.1$647.72+0.4%$1.18 billion$155.07 million36.49
Cerus logo
CERS
Cerus
1.7$6.34+1.3%$1.05 billion$74.65 million-16.26News Coverage
Meridian Bioscience logo
VIVO
Meridian Bioscience
1.7$24.19+0.4%$1.05 billion$253.67 million22.40
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$10.33+0.1%$742.48 million$154.60 million-44.91
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.05+0.2%$679.37 million$123.86 million67.51
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$41.36+2.3%$579.22 million$114.51 million-88.00Gap Down
Utah Medical Products logo
UTMD
Utah Medical Products
0.9$88.57+1.5%$317.93 million$46.90 million27.94
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.